Revvity reported that its diagnostics business grew in Q3 driven by newborn screening and immunodiagnostics, with diagnostics revenue rising 3% year over year. Company executives cited new lysosomal storage disease assays and an expanding newborn sequencing partnership with Genomics England as growth drivers. Management said newborn screening momentum, including CE marking for an expanded lysosomal storage disease panel and a plan for FDA submissions in 2026, positions the business for continued uptake. Revvity highlighted commercial execution and partnerships as levers to scale population screening initiatives. The results illustrate how specialized diagnostic workflows—especially high‑throughput newborn programs—can provide stable revenue islands for lab‑focused players amid broader market variability.